Indicated for type 2 diabetes mellitus to manage blood glucose and support cardiovascular protection.
Mechanism of Action
Canagliflozin inhibits the sodium-glucose co-transporter 2 in the renal proximal tubules. This reduces the reabsorption of filtered glucose and lowers the renal threshold for glucose, promoting its excretion in the urine.
Route of Administration
Oral
Onset Time
1 week
Duration
24 hours
Contraindications
Severe renal impairment, Dialysis, Hypersensitivity to canagliflozin
Information related to Invokana is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
